RE:RE:10 Days LaterRather than release some bland nebulous update I suspect they will wait until they have had time to examine all of the options available.
What are those options ?
I think we know from the AGM that Japan is the #1 potential market for RCH-01. I would assume they are looking for partners to pursue the Japanese market.
It is still unclear whether the Dermal Injector is close to being submitted for FDA approval. Does it need further development ? How close are they to finding a North American manufacturer of the device ? What is the market for the device ? Are there interested companies waiting for the FDA Approval ? At this point what is Mainpointe's role in getting the device to market ?
Less importantly at this point is what is the relationship with Yofoto ? Are they still interested in Replicel or have they walked away ?
Lastly is the question that always comes to mind for me: is there any interest in a Replicel buyout and what would the price be ? With approx. 65,000,000 shares outstanding and a potential 75,000,000 shares if all warrants and options are excercised with the state the company is in presently it might fetch $.25 - $.30 per share. At this point I would take it.